Suzhou, China, and Mölndal, Sweden, October 7, 2026
Suzhou Ribo Life Science Co., Ltd. and its subsidiary Ribocure Pharmaceuticals AB have announced the submission of a European Clinical Trial Application (CTA) for RBD3133, an investigational small interfering RNA (siRNA) therapeutic targeting the INHBE gene. The candidate is being developed for potential future treatment of overweight and obesity, marking an important step in Ribo’s expansion into cardiometabolic diseases. The planned Phase I clinical study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of RBD3133 following subcutaneous administration. The application represents progress toward the first evaluation of this investigational therapy in humans, subject to the applicable regulatory process.
RBD3133 Targets INHBE for Obesity Treatment
RBD3133 is designed to selectively silence INHBE, the gene responsible for encoding inhibin subunit beta E, a protein associated with the production of activin E. Ribo is developing the candidate using RNA interference technology, which is intended to reduce the expression of a specific target gene. The company’s approach is based on human genetic research suggesting that naturally occurring loss-of-function variants in INHBE are associated with healthier fat distribution, improved metabolic characteristics, and lower estimated risks of coronary heart disease and type 2 diabetes. These findings have identified INHBE as a potential therapeutic target for obesity and related metabolic disorders. By targeting the gene through siRNA, RBD3133 is intended to investigate whether modifying this biological pathway could offer a new approach to managing excess body weight and associated cardiometabolic risks.
Obesity affects more than one billion people worldwide, according to the company’s announcement, and is associated with conditions including type 2 diabetes and cardiovascular disease. Although treatment options have advanced, Ribo highlights the continuing need for innovative medicines that address the underlying biology of metabolic dysfunction and may provide durable clinical benefits. RBD3133 is the company’s first candidate being developed specifically for the obesity therapeutic area. Its progress reflects Ribo’s broader strategy of applying RNA interference technology to diseases with substantial unmet medical needs.
Phase I Study to Evaluate Safety and Drug Activity
Advertisement
The proposed Phase I clinical trial is designed as a randomized, placebo-controlled study involving participants with overweight or obesity. Researchers will assess the safety and tolerability of RBD3133, together with its pharmacokinetic and pharmacodynamic characteristics following subcutaneous administration. Safety and tolerability assessments will help determine how participants respond to the investigational therapy, while pharmacokinetic evaluations will examine how the drug behaves in the body. Pharmacodynamic assessments will investigate its biological activity and effects on the intended target pathway. As the first planned human evaluation of RBD3133, the study is expected to establish an initial clinical foundation for subsequent development decisions. However, the CTA submission does not itself confirm regulatory authorization to begin dosing, and the announcement does not report clinical results demonstrating weight loss, improved metabolic outcomes, or long-term safety. The candidate remains investigational, and further studies will be necessary to determine whether its targeted gene-silencing approach can translate into meaningful clinical benefits for people with obesity. Dr. Anders Gabrielsen, Chief Medical Officer of Ribo, described the CTA submission as a step forward for the company’s cardiometabolic pipeline and its efforts to translate human genetic evidence into potential RNA interference medicines.
Ribo Expands Its Cardiometabolic Drug Pipeline
Ribo Life Science focuses on the development and commercialization of siRNA-based therapeutics using vertically integrated technology platforms. Its broader pipeline includes programs targeting cardiovascular and metabolic disorders, liver diseases, kidney diseases, and other therapeutic areas. Ribocure Pharmaceuticals AB, the company’s overseas subsidiary, supports global development of oligonucleotide-based therapies, including asset development and clinical research capabilities. The collaboration between the two companies is intended to advance RBD3133 and support the development of innovative treatments for patients worldwide. The European CTA submission represents a development milestone for Ribo’s obesity program and expands its presence in the cardiometabolic research landscape. Future progress will depend on regulatory clearance, clinical safety findings, evidence of biological activity, and subsequent efficacy studies. If development is successful, RBD3133 could contribute to the growing pipeline of gene-targeted approaches being investigated for obesity and related metabolic conditions.
Source: Suzhou Ribo Life Science press release
